The compelling preclinical record reviewed above calls for clinical trials to test rapamycin or other mTOR inhibitors and/or possibly mTORC2 agonists, beginning in patients with Alzheimer's disease [372]. This evidence concerns the gene MTOR and early-onset autosomal dominant Alzheimer disease.